Genomictree

At a glance

Genomictree filed 29 disclosures in the last 12 months, including 8 insider and 2 buyback. The most recent key filing was on May 22.

Revenue for 2025 was ₩3.8B, up 59.2% on 2024. It made an operating loss of ₩11.3B. Debt was 5% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩1.2B and operating loss of ₩5.7B.

The 2025 annual report lists 76 employees with an average tenure of 5.5 years and average pay of ₩51.8M, #1367 of 1,829 listed companies by average pay. Its 4 directors and auditors were paid ₩305M each on average. It paid no cash dividend for 2025. 안성환 and related parties held 15.78% at year end.

From the 2025 annual report

Staff: 76 (33 men, 43 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩3.9B. Directors and auditors: 4, paid ₩609M in total.

No cash dividend was paid for 2025.

Largest shareholder

안성환 holds 13.33%; with 16 related parties the group holds 15.78% of common shares at year end.

Auditor: 삼덕회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary